TP53 and ovarian carcinoma: Because only 2% of cancers have Y220C p53 mutations [46], PC14586 is currently only being tested in a phase I/II clinical trial (NCT04585750) for patients with solid tumors with Y220C p53 mutations, including ovarian cancer patients [164].